Fluoroethylnormemantine - ReST Therapeutics
Alternative Names: FENM - ReST TherapeuticsLatest Information Update: 16 May 2024
At a glance
- Originator ReST Therapeutics
- Class Adamantanes; Amines; Fluorinated hydrocarbons; Neuroprotectants; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 02 May 2024 ReST Therapeutics withdraws a phase I trial prior to enrolment in for CNS disorders (In volunteers) in Belgium, since a new trial should be designed(PO) (NCT05921929)
- 18 Aug 2023 Chemical structure information added
- 27 Jun 2023 ReST Therapeutics plans a phase-I trial for CNS disorders (In volunteers) in Belgium (NCT05921929)